Cybin announces additional adelia milestone achievement

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a biotechnology company focused on progressing psychedelics to therapeutics™, is pleased to announce that adelia therapeutics inc. (“adelia”), a wholly-controlled subsidiary of cybin, has achieved the milestone identified as y2, q3 (i) as contemplated by the terms of a contribution agreement dated december 4, 2020 (the “transaction agreement”) among cybin, cybin corp., cybin us holdings inc. (the “a
CYBN Ratings Summary
CYBN Quant Ranking